Leerink Partnrs Issues Negative Estimate for Zoetis Earnings

Zoetis Inc. (NYSE:ZTS) – Equities researchers at Leerink Partnrs lowered their Q1 2025 earnings estimates for shares of Zoetis in a research note issued to investors on Monday, February 10th. Leerink Partnrs analyst D. Clark now anticipates that the company will post earnings per share of $1.43 for the quarter, down from their previous forecast of $1.49. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Zoetis’ current full-year earnings is $5.90 per share. Leerink Partnrs also issued estimates for Zoetis’ Q2 2025 earnings at $1.62 EPS, Q3 2025 earnings at $1.64 EPS, Q4 2025 earnings at $1.49 EPS, FY2025 earnings at $6.19 EPS, FY2026 earnings at $6.96 EPS, FY2027 earnings at $7.62 EPS and FY2028 earnings at $8.31 EPS.

Several other equities research analysts have also recently weighed in on the company. Piper Sandler decreased their price target on Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a research report on Monday. Leerink Partners began coverage on Zoetis in a report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target on the stock. UBS Group started coverage on Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 price objective for the company. Morgan Stanley dropped their price objective on shares of Zoetis from $248.00 to $243.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. Finally, Stifel Nicolaus cut their price objective on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $214.00.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $171.71 on Tuesday. The company has a 50-day moving average price of $169.26 and a two-hundred day moving average price of $179.21. The firm has a market capitalization of $77.47 billion, a PE ratio of 32.28, a P/E/G ratio of 2.77 and a beta of 0.90. Zoetis has a twelve month low of $144.80 and a twelve month high of $200.53. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be paid a dividend of $0.50 per share. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.16%. Zoetis’s dividend payout ratio (DPR) is presently 37.59%.

Institutional Trading of Zoetis

Several large investors have recently added to or reduced their stakes in ZTS. Pensionfund Sabic increased its position in shares of Zoetis by 55.6% during the fourth quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock valued at $1,825,000 after buying an additional 4,000 shares during the period. PFW Advisors LLC bought a new stake in Zoetis during the 4th quarter valued at approximately $1,764,000. JPMorgan Chase & Co. grew its holdings in shares of Zoetis by 10.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,916,539 shares of the company’s stock worth $569,834,000 after acquiring an additional 279,092 shares during the period. Simplify Asset Management Inc. bought a new position in shares of Zoetis in the 3rd quarter worth approximately $11,684,000. Finally, Nordea Investment Management AB raised its position in shares of Zoetis by 38.3% in the 4th quarter. Nordea Investment Management AB now owns 2,065,514 shares of the company’s stock worth $336,266,000 after acquiring an additional 572,511 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.